Abstract
A trial of n−3 polyunsaturated fatty acids in the treatment of multiple sclerosis has been conducted over a 5-year period. 312 ambulant patients with acute remitting disease were randomly allocated to treatment and placebo controlled groups. Both were given dietary advice to increase the intake of n−6 polyunsaturated fatty acids and the treatment group in addition received capsules containing n−3 polyunsaturated fatty acids. The results showed no significant difference at the usual 95% confidence level, but there was a trend in favour of the n−3 treated group in all parameters examined including rate of deterioration, frequency and severity of attacks and number of patients improving or remaining unchanged during the course of the trial.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer Science+Business Media New York
About this chapter
Cite this chapter
Bates, D. et al. (1989). Posters. In: Galli, C., Simopoulos, A.P. (eds) Dietary ω3 and ω6 Fatty Acids. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-2043-3_41
Download citation
DOI: https://doi.org/10.1007/978-1-4757-2043-3_41
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-2045-7
Online ISBN: 978-1-4757-2043-3
eBook Packages: Springer Book Archive